Compare EOG Resources Inc (EOG) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EOG Resources Inc vs Incyte Corporation — how do they compare? EOG Resources Inc trades at $138.37 (market cap $73.22B), while Incyte Corporation trades at $116.27 (market cap $22.99B). The key difference: EOG Resources Inc is far larger — about 3.2× Incyte Corporation's market cap, and EOG Resources Inc pays a 2.97% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| EOG | INCY | |
|---|---|---|
Market Cap | $73.22B | $22.99B |
Sector | Energy | Health |
52-Week High | $149.89 | $118.52 |
52-Week Low | $101.78 | $67.38 |
Enterprise Value | $77.68B | $19.01B |
Dividend Yield | 2.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $138.01, down 1.15% on the day, with a bullish technical signal from moving averages and strong analyst support. The company maintains robust profitability with a net income margin of 23.39% and has beaten earnings estimates for the last three quarters. Recent news highlights its valuation discount and operational strength, with a consensus price target of $156.40 suggesting upside potential.
The outlook for EOG is positive, driven by consistent earnings beats, solid cash flow, and a favorable analyst consensus. Key risks include oil price volatility and elevated capital expenditures. The stock presents an opportunity for growth investors seeking exposure to a high-quality energy producer trading below target prices.
Incyte (INCY) trades at $114.88, up 0.57% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive Phase 1/2 data for VGA039 and European regulatory progress for Opzelura highlight pipeline momentum, while Q1 2026 EPS of $1.81 beat expectations by 35%.
The outlook remains positive with 52% analyst buy ratings and a consensus price target of $112.78, though risks include pipeline execution and competitive pressures. Revenue growth to $5.4B projected for 2026 supports valuation, but investors should monitor Q2 earnings due July 28, 2026 for confirmation of trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
